Meda has reached an agreement with Valeant to terminate the companies’
joint
ventures in Canada, Mexico and Australia in the second quarter of 2014.
In all
three countries own Meda affiliates have been established.

The product
rights to Flupirtine, Onsolis and Sublinox are returned to Meda
while Valeant
will continue to run the business in Canada, including the
products Palafer,
Contac, and Manerix. Sublinox will be licensed to Valeant in
Canada.

In
connection with the agreement, Meda will receive additional marketing rights
to
the licensed products Acnatac and Zyclara. Meda will thus be able to sell
these
products in countries such as Australia and South Africa.

As a part of the
total agreement Meda will cease paying royalties on sales of
Acnatac, Aldara
and Zyclara to Valeant.

"The agreement is in line with our strategy to focus -
beside respiratory- on
dermatology, as well as to strengthen our position in
emerging markets", said
Jörg-Thomas Dierks, CEO of Meda AB.

For further
inquiries, please contact:

Paula Treutiger, Investor
Relations
        ph:
+46 733-666 599


                                 
paula.treutiger@meda.se

Meda AB discloses the information provided herein
pursuant to the Securities
Markets Act and/or the Financial Instruments Trading
Act. The information was
submitted for publication on April 7, 2014, at 09:00
CET.

MEDA AB (publ) is a leading international specialty pharma company.
Meda’s
products are sold in more than 120 countries worldwide and the company
is
represented by its own organizations in over 55 countries. The Meda share
is
listed under
Large Cap on the Nasdaq OMX Nordic Stock Exchange in Stockholm.
Find out more,
visit www.meda.se.